BeiGene is a global oncology company that was built differently to deliver innovative medicines faster, more equitably and affordably around the world.

Our founding belief is that there is a better way to bring innovative treatments to patients around the world. We are an oncology powerhouse with a deep, diverse pipeline fueled by one of the industry’s largest and most productive research teams.

Our two foundational medicines, BTK inhibitor BRUKINSA® (zanubrutinib) and PD-1 inhibitor TEVIMBRA® (tislelizumab), demonstrate the strength of our science and our mission to improve treatment outcomes for patients.

Today, more than 10,000 colleagues operate in more than 40 markets across five continents. More than 1 million patients have been treated with our medicines, reflecting our expansive global reach and deep commitment to access.

**Facts at a Glance**

- **10k+** Colleagues globally in over 40 offices on 5 continents
- **$2.5B** Annual product revenue
- **$3.2B** Cash balance
- **1M+** Patients treated with our medicines
- **30+** Assets in clinical and commercial stages
- **3.7k+** Global commercial team members
- **1.1k+** Oncology research team
- **40+** Phase 3 or potentially registration enabling trials
- **~20** Industry collaborations

*As of February 26, 2024

For more information visit:

BeiGene.com
@BeiGeneGlobal
LinkedIn.com/Company/BeiGene
BeiGene Global
Innovative Science Responding to the Greatest Areas of Need

We have one of the largest and most productive oncology research teams in the world, with more than 1,100 highly-credentialed scientists with a proven track record of developing innovative medicines that address significant unmet needs. We also have one of the largest and most compelling oncology pipelines in the industry covering 80% of the world's cancers by incidence.

Global Capabilities to Reach More Patients

We are challenging industry conventions with our own in-house drug discovery and development capabilities. In just over a decade, this model has generated one of the industry’s most robust oncology pipelines, conducted more than 130 clinical trials among more than 20,000 patients, and received regulatory approvals in 70 markets across three internally developed medicines.

Our fully integrated manufacturing capabilities also allow us to speed-up our clinical development efforts while ensuring the highest-quality production of our clinical and commercial portfolio of small-molecule, biologics and emerging modality therapeutics.

The Princeton West Innovation Campus in New Jersey, United States, opening in summer 2024 will house a state-of-the-art, clinical and commercial-stage biologics manufacturing facility and clinical R&D center, which complement our existing capabilities around the world.

For more information visit:

BeiGene.com  @BeiGeneGlobal  Linkedin.com/Company/BeiGene  BeiGene Global